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Glucosamine and Chondroitin Use in Relation
to C-Reactive Protein Concentration:
Results by Supplement Form, Formulation, and Dose
Elizabeth D. Kantor, PhD,1 Kelli O’Connell, MSPH,1 Mengmeng Du, ScD,1 Chao Cao, MPH,2
Xuehong Zhang, ScD,3,4 Dong Hoon Lee, ScD,3 Yin Cao, ScD,2,5,6 and Edward L. Giovannucci, ScD3,4
Abstract

Objectives: Glucosamine and chondroitin supplements have been associated with reduced inflammation, as
measured by C-reactive protein (CRP). It is unclear if associations vary by formulation (glucosamine alone vs.
glucosamine+chondroitin), form (glucosamine hydrochloride vs. glucosamine sulfate), or dose.
Design, Subjects, Setting, Location: The authors evaluated these questions using cross-sectional data collected between 1999 and 2010 on 21,917 US adults, surveyed as part of the National Health and Nutrition
Examination Survey (NHANES).
Exposures: Glucosamine and chondroitin use was assessed during an in-home interview; exposures include
supplement formulation, form, and dose.
Outcome/Analysis: CRP was measured using blood collected at interview. Survey-weighted linear regression
was used to evaluate the multivariable-adjusted association between exposures and log-transformed CRP.
Results: In early years (1999–2004), use of glucosamine (ratio = 0.87; 95% confidence interval [CI] = 0.79–
0.96) and chondroitin (ratio = 0.83; 95% CI = 0.72–0.95) was associated with reduced CRP. However, associations significantly varied by calendar time ( p-interaction = 0.04 and p-interaction = 0.01, respectively), with
associations nonsignificant in later years (ratio = 1.09; 95% CI = 0.94–1.28 and ratio = 1.16; 95% CI = 0.99–1.35,
respectively). Consequently, all analyses have been stratified by calendar time. Associations did not significantly differ by formulation in either set of years; however, significant associations were observed for combined use of glucosamine+chondroitin (ratioearly = 0.82; 95% CI = 0.72–0.95; ratiolate = 1.16; 1.00–1.35), but not
glucosamine alone. Associations also did not significantly differ by supplement form. Even so, a significant inverse association was observed only for glucosamine sulfate in the early years (ratio = 0.78; 95% CI =
0.64–0.95); no significant association was observed for glucosamine hydrochloride. No significant trends were
observed by dose.
Conclusions: Although a significant inverse association was observed for glucosamine and chondroitin
and CRP in early years, this association did not hold in later years. This pattern held for combined use of
glucosamine+chondroitin as well as glucosamine sulfate, although associations did not significantly vary by
supplement form, formulation, or dose. Further study is needed to better understand these associations in the
context of calendar time.
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ften taken for osteoarthritis, glucosamine and
chondroitin are commonly used nonvitamin nonmineral
supplements.1,2 Although the effectiveness of these supplements for joint pain and function remains controversial,3–9 a
growing body of evidence suggests that glucosamine and
chondroitin have anti-inflammatory properties.10–32 In vitro
models have shown that glucosamine and chondroitin inhibit
the activity of nuclear factor kappa B (NFkB), a transcription factor central to the inflammatory cascade, in a dosedependent manner; specifically, research suggests that these
supplements act to inhibit the degradation of NFkB inhibitory
subunit, IkB, blocking NFkB from translocating to the nucleus.10,11,33 Supporting research from animal studies has
demonstrated that administration of glucosamine/chondroitin
reduces inflammatory markers downstream of NFkB.21–26
Several studies have evaluated whether the anti-inflammatory
effect extends to humans.29–31,34,35 Two prior observational
studies suggest glucosamine/chondroitin to be associated
with reduced concentration of C-reactive protein (CRP), a
nonspecific marker of systemic inflammation.29,30 These
results are consistent with those from a small doubleblinded randomized placebo-controlled crossover trial in
which the intervention was 1500 mg of glucosamine hydrochloride +1200 mg of chondroitin sulfate, administered
over a 28-day period.31 A proteomics analysis from this
randomized controlled trial further revealed that the pathway most different between the intervention and placebo
was the ‘‘cytokine activity’’ pathway ( p = 2.6 · 10–16), supporting the hypothesis that glucosamine/chondroitin may reduce inflammation.
Further, in a trial of 53 osteoarthritic patients, 1500 mg of
glucosamine hydrochloride +675 mg of chondroitin significantly reduced concentration of inflammatory marker,
prostaglandin E2.34 However, in a trial of 51 patients with
rheumatoid arthritis, 1500 mg of glucosamine hydrochloride
did not reduce CRP.35 The intervention was glucosamine
alone (rather than glucosamine+chondroitin) and study
participants were able to continue taking their normal drugs.
It is unclear if the lack of association is due to the choice of
supplement formulation (glucosamine alone), form (glucosamine hydrochloride), study design (e.g., rheumatoid
arthritis patients often take strong anti-inflammatories, and
continued use of these drugs would likely conceal differences between groups), or other factors.
Despite a growing body of evidence to suggest that use of
glucosamine/chondroitin is associated with reduced inflammation, it is unclear what characteristics of exposure
may be driving the observed association. Research has also
demonstrated an inverse association with risk of colorectal
cancer and lung cancer36–40; as inflammation is thought to
play a role in the development of these cancers,41–46 this
may offer a plausible biologic mechanism by which these
supplements may reduce risk. Better understanding the
characteristics of exposure associated with inflammation
is critical to moving this body of research forward. The
authors, therefore, evaluated the association between glu-

cosamine and chondroitin use in relation to CRP, by supplement form, formulation, and dose in the National Health
and Nutrition Examination Survey (NHANES).
Methods
Study population

NHANES is a nationally representative cross-sectional
survey of persons living in the United States.47 This analysis
used data from cycles for which relevant data were available (1999–2000 to 2009–2010). Information was collected
during an in-home interview, with further data collection,
physical examination, and blood collection performed at
Mobile Examination Centers.
This analysis includes persons ‡25 years of age who
completed both the in-home interview and blood collection
(n = 26,253); pregnant women were excluded (n = 1398). The
authors further excluded high CRP outliers (top 2% of agegender-body mass index [BMI] groups) to exclude acutely ill
persons (n = 542), as well as those with unreliable diet data
(as determined by NHANES; n = 870), those missing information on supplement use (n = 67), and those missing covariates (n = 1459), resulting in a final n = 21,917.
Exposure

The NHANES interview includes a series of questions
related to use of dietary supplements, from which supplement form, formulation, and dose was assessed.48 Participants indicating use of supplements in the 30 days prior
were asked to show the interviewer the bottles of each
supplement used. When containers were not seen, participants were asked to recall each product taken. This information was linked to a supplement database, which includes
detailed information on ingredients and dose.
Use (yes vs. no) of glucosamine and chondroitin was
defined as use in the 30 days prior. The authors used this
information to determine whether a person used glucosamine (yes vs. no) and chondroitin (yes vs. no), and further
examined associations for supplement formulation (categorized as use of both glucosamine+chondroitin, glucosamine
alone, or neither, with neither as the reference).
A separate analysis, restricted to users, was conducted to
calculate a p-value for the difference between glucosamine+chondroitin versus glucosamine alone. Use of chondroitin alone cannot be studied, given the very small number of
people taking chondroitin in the absence of glucosamine.
Consequently, the association for chondroitin (yes vs. no) is
essentially the same as glucosamine+chondroitin. However, the
authors have maintained the presentation of overall chondroitin
use so as to facilitate ease of comparison with prior studies
before evaluating associations by formulation, form, and dose.
In analyses of supplement form, use of glucosamine was
defined as glucosamine sulfate or glucosamine hydrochloride. The authors excluded persons for whom supplement
form was not known (n = 155) and those who reported use of
glucosamine sulfate and glucosamine hydrochloride (n = 25).
Again, a three-level categorical exposure was used, with no
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use as the reference group. In a separate model limited to
glucosamine users, the authors compared users of glucosamine sulfate with users of glucosamine hydrochloride to
assess the statistical significance of glucosamine form.
For dose, the authors used information on the mg of
glucosamine/chondroitin contained per pill and the number
of pills taken per day to get the average mg/day consumed,
with users categorized as follows: glucosamine (<800 mg/day,
800 to <1200 mg/day, 1200+ mg/day), chondroitin (<500 mg/
day, 500 to <1000 mg/day, 1000+ mg/day). These analyses
were limited to users. In exploratory analyses of duration,
categories defined as follows: glucosamine (£1 year, >1 to
£4 years, >4 years), chondroitin (£1 year, >1 to £3 years, >3
years), with the p-trend calculated among users for whom
this information was available.
Outcome

CRP, an acute-phase protein synthesized as a result of
inflammation, was assessed at the time of interview. CRP
has been associated with both risk of CRC in meta-analyses
of prospective studies49 and has been associated with use of
glucosamine/chondroitin in prior studies.29,30 In NHANES,
serum high-sensitivity CRP (hsCRP) was measured using
latex-enhanced nephelometry.50
Statistical analysis

To normalize the right-skewed distribution of hsCRP, values
were log-transformed using the natural logarithm. Linear regression was used to model the association between exposure
and log-transformed hsCRP. Minimally adjusted models include
gender and age; fully adjusted models additionally include
race/ethnicity, education, smoking, BMI, physical activity,
prescription nonsteroidal anti-inflammatory drug (NSAID) use,
any prescription steroid use, vitamin E use, alcohol intake, coffee
intake, fiber intake, saturated fat intake, dietary omega-3 intake,
omega-3 supplement use, dietary omega-6 intake, statin use,
cancer, diabetes, heart disease, arthritis, and survey cycle. Detailed covariate information is provided in table footnotes.
Given that information on use of any aspirin or nonaspirin
NSAID use was only available for a subset of cycles (1999–
2004), the authors conducted a sensitivity analysis restricted
to these cycles and found that their inclusion did not
meaningfully change effect estimates; therefore, these variables have not been included in the final models.
Results are presented as the exponentiated beta-coefficients,
representing the ratio of geometric mean hsCRP concentrations among persons in the category of interest to those in
the reference category.30 As NHANES is a stratified complex multistage probability-based survey that oversamples
certain population subgroups, all participants have been
assigned analytic weights to account for unequal sampling
probability and nonresponse.
All analyses are stratified by time (early years: 1999–
2004 and later years: 2005–2010), given significant effect
modification by calendar time. To further shed light on associations and understand variation by time, the authors
have explored interaction of glucosamine+chondroitin use
and CRP by the following factors: age, gender, BMI, health
status, and physical activity.
Data were collected by the National Center for Health
Statistics. As de-identified data are publicly available for
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download,47 the Memorial Sloan Kettering Institutional
Review Board determined that this did not constitute human
subjects research. Analyses were conducted using Stata 15
(StataCorp, College Station, TX).
Results

As shown in Table 1, glucosamine+chondroitin users are
more likely than nonusers to be older, non-Hispanic white,
and highly educated. These patterns do not vary over calendar time. Distributions of additional variables are shown
in Supplementary Table S1. Most distributions were comparable by time, with some exceptions. For example, in the
early years (1999–2004), glucosamine+chondroitin users
and nonusers were comparable with regard to health status, with 18% of glucosamine+chondroitin users reporting
poor/fair health status, as compared with 17.3% of nonusers. However, in later years (2005–2010), glucosamine+
chondroitin users were less likely to report fair/poor health
status than nonusers (10.1% vs. 17.9%, respectively). A
similar pattern was observed for diabetes.
The association between glucosamine and CRP varied
by calendar time ( p-interaction = 0.04), with a statistically significant inverse association between glucosamine and CRP in
early years (ratio = 0.87; 95% confidence interval [CI] = 0.79–
0.96), and no association in later years (ratio = 1.09; 95%
CI = 0.94–1.28) (Table 2). A comparable pattern was observed
for chondroitin ( p-interaction = 0.01), again with a significant
inverse association in early years (ratio = 0.83; 95% CI = 0.72–
0.95) and a nonsignificant positive association in later years
(ratio = 1.16; 95% CI = 0.99–1.35).
When examined by supplement formulation, the authors
observed a significant inverse association for use of glucosamine+chondroitin as compared with use of neither in
early years (ratio = 0.82; 95% CI = 0.72–0.95); no association was observed for use of glucosamine alone (ratio =
0.96; 95% CI = 0.80–1.14); however, the difference between
combined use and use of glucosamine alone did not reach
statistical significance ( p-value = 0.12). Conversely, a positive
association was observed for combined use of glucosamine+
chondroitin in the later years (ratio = 1.16; 95% CI = 1.00–
1.35), again with no association observed for glucosamine
alone (ratio = 0.95; 95% CI = 0.74–1.22). Again, the direct
comparison of glucosamine+chondroitin as compared with
glucosamine alone in later years was not statistically significant ( p-value = 0.08). The interaction across years was
significant ( p-interaction = 0.03).
In early years, there was a statistically significant inverse
association for glucosamine sulfate and CRP (ratio = 0.78;
95% CI = 0.64–0.95) and a nonsignificant inverse association was observed between glucosamine hydrochloride and
CRP (ratio = 0.86; 95% CI = 0.72–1.05); the difference by
supplement form was not significant ( p-value = 0.21). No
significant associations were observed by supplement form
in later years ( p-value = 0.38). A p-interaction = 0.05 was
observed for the interaction between supplement form and
calendar time.
When examining associations by dose, no statistically
significant associations were observed in early years or in
later years, nor did the association significantly vary by
time. Furthermore, no significant associations were observed
in exploratory analyses of duration in early or later years.
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3079 (19.8)
2263 (25.8)
2370 (28.9)
1828 (25.5)
2865 (33.1)
3551 (35.8)
1882 (18.7)
1242 (12.5)
4690 (48.9)
2756 (27.4)
1246 (12.3)
848 (11.5)

3139 (19.3)
2355 (25.6)
2487 (29.0)
1950 (26.1)
2970 (32.8)
3697 (35.8)
1966 (18.8)
1298 (12.6)
4889 (49.1)
2915 (27.8)
1262 (11.9)
865 (11.2)

(74.3)
(9.9)
(6.5)
(9.3)

4952
1741
2141
706

5262
1762
2183
724

(75.0)
(9.6)
(6.3)
(9.1)

4845 (49.3)
4695 (50.7)

5034 (49.2)
4897 (50.8)

(32.9)
(23.7)
(18.3)
(12.8)
(8.5)
(3.8)

2529
1902
1423
1695
1221
770

2549
1939
1492
1817
1305
829

(31.8)
(23.2)
(18.7)
(13.5)
(8.9)
(3.9)

9540 (95.4)

9931 (100)

Overall
N (Weighted %)a

AA, associate degree; GED, general educational development.

Overall
Age (years)
25 to <40
40 to <50
50 to <60
60 to <70
70 to <80
80+
Sex
Male
Female
Race/ethnicity
Non-Hispanic white
Non-Hispanic black
Mexican American
Other
Education
Less than high school
High school grad/GED
or equivalent
Some college or
AA degree
College grad or above
<25 (Underweight/
normal)
25 to <30 (Overweight)
30 to <35 (Obese)
35+ (Severely obese)
Smoking
Never
Former
Current: low
(£15 cigarettes/day)
Current: high
(>15 cigarettes/day)

Variable

2005–2010

(11.4)
(17.0)
(26.3)
(29.6)
(10.9)
(4.7)

(91.7)
(2.6)
(2.1)
(3.6)

6 (4.8)

70 (56.7)
42 (33.2)
7 (5.3)

46 (35.0)
27 (23.0)
23 (17.2)

42 (40.6)
29 (24.7)

34 (31.1)

19 (6.9)
30 (21.4)

99
7
13
6

56 (44.0)
69 (56.0)

10
18
22
38
19
18

125 (1.6)
(6.7)
(10.9)
(28.3)
(29.1)
(18.6)
(6.3)

(89.4)
(2.1)
(1.9)
(6.6)

11 (6.0)

129 (51.0)
116 (39.9)
8 (3.1)

100 (34.9)
57 (21.9)
32 (13.5)

80 (35.9)
75 (29.6)

83 (30.7)

39 (11.1)
62 (22.3)

210
14
28
12

131 (49.3)
133 (50.7)

10
18
47
84
64
41

264 (3.0)
(29.4)
(22.3)
(21.2)
(14.3)
(8.5)
(4.4)

(73.5)
(10.2)
(7.3)
(9.0)

944 (9.4)

6171 (51.4)
3281 (26.7)
1590 (12.6)

4211 (34.5)
2596 (20.5)
1960 (15.5)

2533 (28.3)
3219 (29.5)

3211 (29.7)

3396 (17.8)
2846 (24.2)

6130
2270
2111
1475

6009 (48.3)
5977 (51.7)

3150
2297
2059
2154
1499
827

11,986 (100)
(30.7)
(22.8)
(20.7)
(13.5)
(8.1)
(4.2)

(72.7)
(10.6)
(7.6)
(9.1)

923 (9.7)

5869 (51.4)
3057 (25.9)
1564 (13.0)

3992 (34.2)
2474 (20.6)
1866 (15.5)

2350 (27.8)
3081 (29.7)

3038 (29.6)

3301 (18.3)
2724 (24.3)

5721
2226
2058
1408

5718 (48.5)
5695 (51.5)

3112
2237
1948
1992
1366
758

11,413 (94.6)

(7.5)
(10.6)
(33.5)
(30.6)
(12.6)
(5.3)

(87.2)
(2.1)
(4.9)
(5.7)

11 (8.4)

90 (51.2)
52 (37.3)
5 (3.1)

70 (40.0)
31 (16.5)
20 (13.7)

48 (32.3)
37 (29.8)

44 (27.9)

31 (9.9)
35 (29.8)

106
9
22
21

72 (40.9)
86 (59.1)

12
22
31
50
30
13

158 (1.5)

(6.5)
(13.8)
(28.2)
(27.6)
(16.3)
(7.7)

(88.0)
(2.8)
(2.2)
(7.1)

10 (2.8)

206 (51.4)
168 (40.0)
21 (5.7)

146 (38.0)
90 (21.7)
71 (16.3)

133 (38.5)
98 (24.0)

122 (31.9)

64 (9.1)
86 (20.6)

296
35
31
43

213 (46.9)
192 (53.1)

25
36
80
108
101
55

405 (3.9)

No use of
Any use of
Combined use
No use of
Any use of
Combined use
glucosamine
glucosamine
of glucosamine+
glucosamine or
glucosamine
of glucosamine+
or chondroitin
only
chondroitin
Overall
chondroitin
only
chondroitin
N (Weighted %) N (Weighted %) N (Weighted %) N (Weighted %)b N (Weighted %) N (Weighted %) N (Weighted %)

1999–2004

Table 1. Distribution of Participant Characteristics, by Glucosamine+Chondroitin Use and Survey Cycle (1999–2004 and 2005–2010)
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N (Wgt %)

Chondroitin dose (mg)
Use, <500
Use, 500 to <1000
Use, 1000+
147 (55.2)
63 (3.07)
40 (14.1)

Overall use variables
Glucosamine
No use
9542 (95.4)
Use
389 (4.6)
Chondroitin
No use
9665 (97.0)
Use
266 (3.0)
Use, by supplement formulation
Glucosamine+chondroitin
Use of neither
9540 (95.4)
Use of glucosamine alone
125 (1.6)
Use of both
264 (3.0)
Both versus glucosamine alonec
Use, by supplement form
Glucosamine
No use
9540 (96.6)
Use of glucosamine sulfate
131 (1.6)
Use of glucosamine HCl
154 (1.8)
Glucosamine HCl versus glucosamine sulfated
Use, by supplement dose (among users)
Glucosamine dose (mg)
Use, <800
231 (59.9)
Use, 800 to <1200
68 (22.1)
Use, 1200+
73 (18.1)

Variable

REF
0.67–0.90
REF
0.75–1.23
0.67–0.90
p: 0.05
REF
0.57–1.02
0.68–1.12
p: 0.54

REF
0.78
1
0.96
0.78

1
0.76
0.88

1
REF
0.90
0.64–1.28
1.28
0.94–1.74
p-trend: 0.42

1
REF
0.86
0.56–1.33
0.85
0.61–1.20
p-trend: 0.29

REF
0.73–0.96

95% CI

1
0.84

Ratio

REF
0.64–0.95
0.72–1.05
p: 0.21

REF
0.80–1.14
0.72–0.95
p: 0.12

REF
0.72–0.95

REF
0.79–0.96

95% CI

1
REF
1.08
0.85–1.39
1.27
0.95–1.69
p-trend: 0.11

1
REF
1.08
0.78–1.48
1.01
0.79–1.26
p-trend: 0.88

1
0.78
0.87

1
0.96
0.82

REF
0.83

1
0.87

Ratio

163 (41.4)
115 (27.3)
122 (31.3)

271 (48.7)
92 (15.1)
197 (36.2)

11,413 (95.2)
92 (1.0)
395 (3.8)

11,413 (94.6)
158 (1.5)
405 (3.9)

11,571 (96.0)
415 (4.0)

11,423 (94.6)
563 (5.4)

N (Wgt %)

REF
0.73–1.66
0.81–1.19
p: 0.56

REF
0.61–1.13
0.87–1.26
p: 0.18

REF
0.87–1.27

REF
0.83–1.16

95% CI

1
REF
0.96
0.67–1.38
0.99
0.70–1.41
p-trend: 0.95

1
REF
0.83
0.55–1.24
1.13
0.88–1.45
p-trend: 0.37

1
1.10
0.99

1
0.83
1.05

1.00
1.05

1
0.98

Ratio

Age and gender
adjusteda

Age and gender
adjusteda
Multivariable
adjustedb

2005–2010

1999–2004

REF
0.91–1.57
0.89–1.32
p: 0.38

REF
0.74–1.22
1.00–1.35
p: 0.08

REF
0.99–1.35

REF
0.94–1.28

95% CI

1
REF
0.87
0.63–1.20
0.95
0.71–1.28
p-trend: 0.71

1
REF
0.93
0.70–1.24
1.13
0.93–1.37
p-trend: 0.24

1
1.20
1.09

1
0.95
1.16

1
1.16

1
1.09

Ratio

Multivariable
adjustedb

(continued)

0.63

0.55

0.05

0.03

0.01

0.04

p-interaction

Table 2. Association Between Glucosamine and Chondroitin Supplement Use, and C-Reactive Protein, by Form, Formulation, and Dose
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95% CI

1
REF
1.06
0.68–1.66
0.83
0.59–1.15
p-trend: 0.39

1
REF
1.02
0.71–1.48
0.78
0.57–1.06
p-trend: 0.26

Ratio

95% CI

1
REF
1.34
0.92–1.82
1.00
0.72–1.40
p-trend: 0.77

1
REF
1.16
0.88–1.53
0.92
0.69–1.23
p-trend: 0.92

Ratio

N (Wgt %)

142 (31.7)
94 (22.4)
169 (45.9)

206 (32.8)
152 (27.9)
205 (39.4)

95% CI

1
REF
0.84
0.54–1.31
0.77
1.08–2.08
p-trend: 0.16

1
REF
0.88
0.58–1.33
0.79
0.54–1.16
p-trend: 0.22

Ratio

95% CI

1
REF
0.84
0.57–1.22
0.78
0.57–1.06
p-trend: 0.12

1
REF
0.91
0.64–1.28
0.89
0.62–1.26
p-Trend: 0.49

Ratio

Multivariable
adjustedb

0.32

0.04

p-interaction

b

Adjusted for age (25–39, 40–49, 50–59, 60–69, 70–79, and 80+) and gender.
Adjusted for gender, age (25–39, 40–49, 50–59, 60–69, 70–79, and 80+), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), education (less than high school,
high school grad or equivalent, some college or AA degree, and college grad or above), smoking (never, former, £15 cigarettes/day if current, and >15 cigarettes/day if current), BMI
(underweight/normal, overweight, obese, and severely obese), physical activity (none, any moderate, and any vigorous), any prescription NSAID use, any prescription steroid use, any non-MVMM
vitamin E use, alcohol intake (<1 drink/month, ‡1 drink/month to <4 drinks/week, ‡4 drinks/week to <2 drinks/day, and ‡2 times/day), coffee intake (quartiles), fiber intake (quartiles), saturated fat
intake (quartiles), dietary omega-3 intake (quartiles), any non-MVMM omega-3 supplement use, dietary omega-6 intake (quartiles), statin use, cancer, diabetes, heart disease, arthritis, and survey
cycle.
c
p-Value estimated directly comparing users of glucosamine alone with users of glucosamine+chondroitin, in a model restricted to users.
d
p-Value estimated directly comparing users of glucosamine sulfate with users of glucosamine hydrochloride, in a model restricted to users.
BMI, body mass index; MVMM, multivitamin, multimineral; NSAID, nonsteroidal anti-inflammatory drug.

a

123 (46.7)
80 (30.2)
61 (23.1)

188 (47.8)
129 (34.3)
71 (18.0)

Use, by duration (among users)
Glucosamine (years)
£1 year
>1 to £4 years
>4 years

Chondroitin (years)
£1 year
>1 to £3 years
>4 years

N (Wgt %)

Variable

Age and gender
adjusteda

Age and gender
adjusteda
Multivariable
adjustedb

2005–2010

1999–2004

Table 2. (Continued)
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No significant interaction was observed between glucosamine+chondroitin and age, gender, BMI, health status, or
physical activity within either time period (Supplementary
Tables S2 and S3).
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Discussion

In this nationally representative survey, the authors observed
no clear overall pattern of association between glucosamine and
chondroitin and CRP, by supplement formulation, form, and
dose—in large part, due to unexpected strong effect modification by time. Specifically, they observed a significant inverse
association for glucosamine/chondroitin in early years, and an
unexpected null association in later years.
Although the geometric mean of CRP did not significantly
differ when directly comparing users of glucosamine+chondroitin to users of glucosamine alone, it should be noted that
as compared with nonuse significant associations were observed for use of glucosamine+chondroitin (inverse association with CRP in early years, positive association in later
years), whereas no significant associations were observed for
use of glucosamine alone. Associations with CRP did not
significantly differ when directly comparing supplements by
form (glucosamine sulfate vs. hydrochloride), although a
significant inverse association was only observed for glucosamine sulfate in the early years. No significant trends were
observed by dose, nor in exploratory analyses of duration.
In this study, the authors observed an inverse association
between use of glucosamine and CRP in the early years,
with a null association in later years. A comparable pattern
of association was observed for chondroitin use. Although
the inverse association in early years aligned with expectation and the prior literature,29–31,34 it is unclear why the
association changed over time.
It is conceivable that this pattern may be driven by changing
characteristics of exposure over time. In this study, the authors
have evaluated patterns by supplement formulation, form, and
dose, but it is possible that there are other unmeasured characteristics of exposure, such as supplement quality, which have
changed over time. It is also possible the factors associated with
use have changed over time in a way not captured by covariate
adjustment, resulting in the observed pattern of association. For
example, if there is an unmeasured healthy behavior more
strongly associated with use in the early years, such a variable
could potentially explain the pattern of results if also associated
with CRP. However, the authors have carefully adjusted for
many healthy behaviors, and it is hard to imagine a variable that
could explain this pattern of results.
It is also possible that there may be an effect modifier that
changed in prevalence over time, which could explain observed pattern of association; however, there was no evidence of effect modification for the factors examined.
Although this pattern of results does raise the potential of
bias or chance, it should be noted that the prior literature
does largely support an inverse association with inflammation, including two small trials (which should not be subject
to concerns of residual confounding).29–31,34,35
When evaluating whether the association varied by supplement formulation, the authors observed no significant
difference in the geometric mean CRP for users of glucosamine+chondroitin as compared with users of glucosamine
alone. This held in both early and later years. However, it
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should be noted that the significant associations were only
observed for glucosamine+chondroitin (inverse in early
years, positive in later years), with no significant associations observed for glucosamine alone. Approximately 70%
of glucosamine in the U.S. population is taken in conjunction with chondroitin and nearly all chondroitin is taken
with glucosamine (a reflection of the supplement products
available on the market). Thus, the sample size is smaller for
glucosamine alone and the authors cannot rule out modest
effect estimates pertaining to use of glucosamine alone.
However, this pattern in the early years is consistent with
what has been observed elsewhere: in exploratory analyses
conducted in studies of inflammation, oxidative stress, and
CRC, the association has been consistently stronger for
glucosamine+chondroitin than for glucosamine alone.29,36,37,51
These analyses suggest that the biologic effect may be driven by chondroitin or the combination of glucosamine+
chondroitin, rather than glucosamine alone; however, prior
exploratory analyses of glucosamine alone were quite underpowered, with wide CIs limiting the interpretation of
the null association for glucosamine alone.
Even so, it is unclear why the association for
glucosamine/chondroitin would change direction over time. It
is possible that this pattern reflects some change in the glucosamine+chondroitin supplements available (or the chondroitin
component). It is also possible that the association between
glucosamine+chondroitin and CRP could be differentially
confounded in early and late years. Further research in a large
study will be needed to better understand this question, preferably one with recent data to reflect current patterns of use.
Associations also did not significantly differ by supplement
form (glucosamine sulfate vs. hydrochloride). However, the
significant inverse association in the early years was only
observed for glucosamine sulfate, with no significant association observed for glucosamine hydrochloride. Although trials
have largely used glucosamine hydrochloride as the experimental agent,3,31,34,35 glucosamine sulfate accounts for *30%
of use in the population, and it was unknown if the association
with inflammation differs by supplement form. In this study,
there is some suggestion that the early inverse association is
reflected by glucosamine sulfate, although a nonsignificant
inverse association was also observed for glucosamine hydrochloride in the early years.
Although prior studies have not directly compared glucosamine hydrochloride and sulfate, prior trials of inflammation have used glucosamine hydrochloride and have
observed significant reductions in inflammation, unlike this
study. No significant associations were observed in later
years. Again, an explanation for why this pattern was observed over time remains unclear. It is possible that there is
a change to the quality of supplements over time or some
other change to an unmeasured characteristic of these supplements or their users. Although the authors have been
extensive with covariates included, it is possible that there is
an unknown/unmeasured factor differentially confounding
results over time, given changes in prevalence and/or changes
in the strength of association with either the exposure or
outcome. The impact of chance also cannot be ruled out.
The authors also evaluated whether the relationship between glucosamine/chondroitin and CRP strengthened with
increasing dose. Evidence of a ‘‘dose–response’’ relationship would lend credibility to a true biologic effect, while
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also informing the dose needed to observe an association
with inflammation. In this study, no such significant trend
was observed, raising a question about whether the inverse
association in early years might reflect bias or chance, rather
than a true causal association. A similar pattern was observed in exploratory analyses of duration. Given the lack
of prior study on these specific questions, they should be
evaluated in a contemporary large study.
This study leverages rich data on supplement use in a
large nationally representative population of U.S. adults.
NHANES has extensive covariate data, enabling a wellcontrolled analysis. This is the first study to evaluate whether the association between glucosamine and chondroitin
and inflammation varies by supplement form and dose, and
offers a large sample size to evaluate whether the association varies by supplement formulation—a question only
previously evaluated in small exploratory analyses.
Given strong effect modification by time, all results had
to be stratified by time, cutting power to evaluate associations of interest, also precluding defining exposure by regular use, so as to not further reduce power. However, most
glucosamine/chondroitin users take the supplements regularly.2 In exploratory analyses, duration was assessed for the
particular supplement used, and may not reflect total duration of use of a given ingredient; thus, these durationspecific analyses should be interpreted as exploratory. Although supplement use was assessed in the prior 30 days
(reflecting exposure before CRP measurement), it is always
possible that use in this period may not reflect use in the
etiologically relevant timeframe. Finally, although the authors have taken extensive effort in covariate adjustment, it
is conceivable that there is some residual confounding, and
if the degree of confounding varies over time, this could
give rise to the unexpected change in association over time.
In conclusion, in this nationally representative study, the
authors observed no clear pattern of association between
glucosamine and chondroitin use and CRP, largely due to
the unexpected variation over calendar time. Although inverse associations in early years support prior study, null
and/or positive associations in later years suggest that further research is needed to better understand why these
associations changed over time, and if they reflect a true
change in exposure, bias, or chance.
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